{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:10:40Z","timestamp":1780920640482,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":57,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101161","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:50:55Z","timestamp":1772265055000},"page":"101161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia"],"prefix":"10.1016","volume":"47","author":[{"given":"Mounzer E","family":"Agha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C","family":"De Braganca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Lengil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"De Wiest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Perciavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-2659","authenticated-orcid":false,"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101161_bib0001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3892\/ol.2022.13610","article-title":"Clinical characteristics of second primary malignancies among first primary malignancy survivors: a single-center study, 2005-2020","volume":"25","author":"Geng","year":"2023","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101161_bib0002","article-title":"Secondary primary malignancies in multiple myeloma: an old nemesis revisited","volume":"2012","author":"Yang","year":"2012","journal-title":"Adv. Hematol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101161_bib0003","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood.V12.9.788.788","article-title":"Leukemia or lymphoma and coexistent primary malignant lesions: a review of the literature and a study of 120 cases","volume":"12","author":"Moertel","year":"1957","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101161_bib0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1158\/1055-9965.EPI-06-1069","article-title":"Non-Hodgkin lymphoma secondary to cancer chemotherapy","volume":"16","author":"Krishnan","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101161_bib0005","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJM197211302872204","article-title":"Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy","volume":"287","author":"Arseneau","year":"1972","journal-title":"N. Engl. J. Med."},{"issue":"45","key":"10.1016\/j.ctarc.2026.101161_bib0006","doi-asserted-by":"crossref","first-page":"78261","DOI":"10.18632\/oncotarget.20876","article-title":"Second cancer risk following Hodgkin lymphoma","volume":"8","author":"Sud","year":"2017","journal-title":"Oncotarget."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101161_bib0007","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101161_bib0008","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2017.06.028","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a United States population-based study","volume":"17","author":"Giri","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ctarc.2026.101161_bib0009","article-title":"Second primary malignancies post autologous stem-cell transplant in multiple myeloma from India \u2013 knowing the unknown","author":"Mirgh","year":"2025","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101161_bib0010","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3324\/haematol.2019.244780","article-title":"Second malignancies after treatment of childhood non-hodgkin lymphoma: a report of the berlin-frankfurt-muenster study group","volume":"106","author":"Moser","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101161_bib0011","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101161_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-020-00400-4","article-title":"Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients","volume":"11","author":"Rosenberg","year":"2021","journal-title":"Blood Cancer J."},{"issue":"26","key":"10.1016\/j.ctarc.2026.101161_bib0013","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s Lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101161_bib0014","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1016\/S2352-3026(23)00212-0","article-title":"Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study","volume":"10","author":"Trab","year":"2023","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101161_bib0015","article-title":"Second primary malignancies in diffuse large b-cell lymphoma survivors with 40 years of follow up: influence of chemotherapy and radiation therapy","volume":"7","author":"Rock","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.ctarc.2026.101161_bib0016","article-title":"Cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101161_bib0017","article-title":"CAR-T cell therapy for hematological malignancies: history, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101161_bib0018","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101161_bib0019","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101161_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101161_bib0021","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101161_bib0022","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101161_bib0023","unstructured":"FDA investigating serious risk of t-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies [press release]. 2023."},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2026.101161_bib0024","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1182\/blood-2024-199931","article-title":"Systematic review of secondary primary malignancies (SPMs) in patients treated with chimeric antigen receptor T-Cell (CAR-T) therapies","volume":"144","author":"Agha","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2026.101161_bib0025","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1182\/blood-2024-198825","article-title":"Second primary malignancies after CAR T-cell therapy: a systemic review","volume":"144","author":"Shahzad","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ctarc.2026.101161_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115688","article-title":"CAR-T cell therapy: from the shop to cancer therapy","volume":"24","author":"Uscanga-Palomeque","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101161_bib0027","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/bloodadvances.2024013243","article-title":"Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults","volume":"8","author":"Lamble","year":"2024","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101161_bib0028","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI130144","article-title":"CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration","volume":"130","author":"Nobles","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"7897","key":"10.1016\/j.ctarc.2026.101161_bib0029","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101161_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101161_bib0031","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"issue":"39","key":"10.1016\/j.ctarc.2026.101161_bib0032","first-page":"663","article-title":"Randomized controlled trials: part 17 of a series on evaluation of scientific publications","volume":"108","author":"Kabisch","year":"2011","journal-title":"Dtsch. Arztebl. Int."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101161_bib0033","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1097\/PRS.0b013e3181f44abc","article-title":"Observational studies: cohort and case-control studies","volume":"126","author":"Song","year":"2010","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.ctarc.2026.101161_bib0034","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.ctarc.2026.101161_bib0035","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-Cell therapy: a systematic review and meta-analysis of 5517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101161_bib0036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40364-023-00509-1","article-title":"Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies","volume":"11","author":"Dabiri","year":"2023","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101161_bib0037","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12885-019-5677-2","article-title":"Portrait of a cancer: mutational signature analyses for cancer diagnostics","volume":"19","author":"Van Hoeck","year":"2019","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.ctarc.2026.101161_bib0038","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S2152-2650(24)02346-2","article-title":"OA-65 Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (Len)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update","volume":"24","author":"Mateos","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101161_bib0039","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101161_bib0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:41:41Z","timestamp":1780918901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":40,"alternative-id":["S2468294226000729"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101161","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101161"}}